Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods
https://doi.org/10.65249/1027-7218-2026-9-24-34
Abstract
Objective. To characterize clinical severity of COVID-19 in hospitalized patients during pandemic periods and to assess the effect of vaccination on disease course.
Materials and methods. Single-centre retrospective cohort study of 11,203 patients hospitalized with COVID-19 in 2020– 2023 (112,455 bed-days). Clinical severity was graded on a four-level respiratory failure scale: «none»; «oxygen mask/cannula»; «noninvasive ventilation» (NIV); «invasive mechanical ventilation» (IMV). Bayesian hierarchical ordinal regression was fitted with covariates: age, Elixhauser comorbidity index, vaccination, previous-day respiratory failure, pandemic day and disease days. Statistical analysis was performed with programming languages R 4.6.0 and Stan 2.38.0.
Results. The 28-day cumulative risk of respiratory failure was up to 50 % in the first wave, up to 80 % in the period of Alpha variant predominance, > 90 % (unvaccinated) and ≤ 65 % (vaccinated) in the period of Delta variant predominance, and ≤ 25 % in the Omicron. During predominance of Delta variant, the probability of NIV/IMV reached 25–30 % in older unvaccinated patients with comorbidities compared to ≤ 4.5 % in vaccinated ones; during predominance of Omicron variants it was < 1 %, though up to 20 % still required oxygen. After standardization, vaccination was associated with a lower cumulative risk from September 2021 to March 2022, peaking in December 2021: -24.3 % (95 % CI (-17,6; -30,6)).
Conclusion. Respiratory failure severity varied by pandemic period, and vaccination against SARS-CoV-2 had a protective effect in hospitalized patients.
About the Authors
D. LitvinchukBelarus
D. Danilau
Belarus
I. Karpov
Belarus
References
1. WHO. WHO COVID-19 dashboard. 2026. Available at: https://data.who.int/dashboards/covid19/summary (accessed: 07.08.2026).
2. Rahimi A., Mirzazadeh A., Tavakolpour S. Genetics and genomics of SARS-CoV-2. Genom. 2021; 113(1). doi:10.1016/j.ygeno.2020.09.059.
3. Volz E., Mishra S., Chand M., et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 2021; 593 (7858). doi:10.1038/s41586-021-03470-x.
4. Twohig K.A., Nyberg T., Zaidi A., et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 Delta (B.1.617.2) compared with Alpha (B.1.1.7) variants of concern. Lancet Infect Dis. 2022; 22(1): 35–42.
5. Tian D., Sun Y., Xu H., Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol. 2022; 94(6). doi:10.1002/jmv.27643.
6. Relan P., Motaze N.V., Kothari K., et al. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages. BMJ Glob Health. 2023; 8(7). doi:10.1136/bmjgh-2023-012328.
7. Bast E., Tang F., Dahn J., Palacio A. Increased risk of hospitalisation and death with the Delta variant in the USA. Lancet Infect Dis. 2021; 21(12). doi:10.1016/S1473-3099(21)00685-X.
8. Adjei S., Hong K., Molinari N.A.M., et al. Mortality risk among patients hospitalized primarily for COVID-19 during the Omicron and Delta variant pandemic periods – United States, April 2020 – June 2022. MMWR. 2022; 71(37). doi:10.15585/mmwr.mm7137a4.
9. Dashkevich A., Kolomiets N. Characteristics of the epidemic process of COVID-19 in the Republic of Belarus. Klinicheskaya infektologiya i parazitologiya. 2024; 13(1): 70–80. (in Russian)
10. Mitchell W.B. Thromboinflammation in COVID-19 acute lung injury. Paediatr Respir Rev. 2020; 35: 20–24.
11. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine. The Lancet. 2021; 397(10275). doi:10.1016/s0140-6736(21)00234-8.
12. Rahmani K., Shavaleh R., Forouhi M., et al. The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19. Front Public Health. 2022; 10. doi:10.3389/fpubh.2022.873596.
13. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8). doi:10.1016/s1473-3099(20)30483-7.
14. Gasparini A. comorbidity: an R package for computing comorbidity scores. J Open Source Softw. 2018; 3(23). doi: 10.21105/joss.00648.
15. Gelman A., Carlin J.B., Stern H.S., et al. Bayesian Data Analysis. 3rd ed. Boca Raton: Chapman & Hall/CRC; 2013. 675. doi: 10.1201/b16018.
16. Rohde M.D., French B., Stewart T.G., Harrell Jr. F.E. Bayesian transition models for ordinal longitudinal outcomes. Stat Med. 2024; 43(18). doi: 10.1002/sim.10133.
17. Stan Development Team. Stan modeling language user’s guide and reference manual (Version 2.39). Available at: https://mc-stan.org (accessed: 07.08.2026).
18. Burkner P.C. Bayesian item response modeling in R with BRMS and Stan. J Stat Softw. 2021; 100(5): 1–54.
19. R Core Team. R: a language and environment for statistical computing. Vienna : R Foundation for Statistical Computing; 2026. Available at: https://www.R-project.org. (accessed: 07.08.2026).
Review
For citations:
Litvinchuk D., Danilau D., Karpov I. Clinical characteristics and efficacy of vaccination on severity in hospitalized patients with COVID-19 during different pandemic periods. Healthcare. 2026;1(9):24-34. (In Russ.) https://doi.org/10.65249/1027-7218-2026-9-24-34
JATS XML
